|Mr. Michael S. Richman||Co-Founder, CEO, Pres & Director||N/A||N/A||1961|
|Dr. Lieping Chen M.D., Ph.D.||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||1957|
|Mr. Steven P. Cobourn||Chief Financial Officer||N/A||N/A||1963|
|Dr. Solomon Langermann||Chief Scientific Officer||N/A||N/A||1960|
|Dr. Timothy Mayer Ph.D.||Sr. VP of Corp. Devel.||N/A||N/A||1965|
NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.
NextCure, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.